The Mechanism of Action of CDK4/6 Inhibitors

Conference Correspondent  - SABCS 2017 - Breast Cancer, Breast Cancer, Video
Matthew P. Goetz, MD
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Related Items
Long-Term Data from the TEAM Trial Support Individualized Adjuvant Endocrine Therapy Strategy for Postmenopausal Women with HR-Positive Early Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Results of DATA Study Failed to Show Benefits for Extended Endocrine Therapy in Women with Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
BRCA1/2 Status Affects Response to Polychemotherapy in Triple-Negative Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Do Hormonal Contraceptives Increase the Risk for Breast Cancer?
TON Web Exclusives published on December 28, 2017 in Breast Cancer
HER2 CAR T-Cell Delivery for Treating Multifocal Brain Metastases
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Questions About Treating Patients on a CDK4/6 Inhibitor
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer, Breast Cancer, Video
The Use of Chemotherapy in the Metastatic Setting
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer, Breast Cancer, Video
New Oral SERD Elacestrant Shows Efficacy in Breast Cancer Harboring ESR1 Mutations
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer
CDK6 Could Be a Key Factor for Efficacy of CDK4/6 Inhibitors and the Hormone Sensitivity Following Acquired Resistance
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer
Last modified: January 10, 2018